Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale by Reddy, Venkatesh Pilla et al.
Population Pharmacokinetic-Pharmacodynamic Modeling of
Haloperidol in Patients With Schizophrenia Using Positive
and Negative Syndrome Rating Scale
Venkatesh Pilla Reddy, PhD,* Magdalena Kozielska, PhD,* Martin Johnson, PhD,*
Nyashadzaishe Mafirakureva, MSc,* An Vermeulen, PhD,Þ Jing Liu, PhD,þ Rik de Greef, MSc,§
Dan Rujescu, PhD,|| Geny M.M. Groothuis, PhD,* Meindert Danhof, PhD,¶
and Johannes H. Proost, PhD*
Abstract: The aim of this study was to develop a pharmacokinetic-
pharmacodynamic (PKPD) model that quantifies the efficacy of haloperi-
dol, accounting for the placebo effect, the variability in exposure-response,
and the dropouts. Subsequently, the developed model was utilized to char-
acterize an effective dosing strategy for using haloperidol as a comparator
drug in future antipsychotic drug trials. The time course of plasma halo-
peridol concentrations from 122 subjects and the Positive and Negative
Syndrome Scale (PANSS) scores from 473 subjects were used in this anal-
ysis. A nonlinear mixed-effects modeling approach was utilized to describe
the time course of PK and PANSS scores. Bootstrapping and simulation-
based methods were used for the model evaluation. A 2-compartment
model adequately described the haloperidol PK profiles. The Weibull
and Emax models were able to describe the time course of the placebo and
the drug effects, respectively. An exponential model was used to account
for dropouts. Joint modeling of the PKPD model with dropout model in-
dicated that the probability of patients dropping out is associated with the
observed high PANSS score. The model evaluation results confirmed that
the precision and accuracy of parameter estimates are acceptable. Based on
the PKPD analysis, the recommended oral dose of haloperidol to achieve a
30% reduction in PANSS score from baseline is 5.6 mg/d, and the corre-
sponding steady-state effective plasma haloperidol exposure is 2.7 ng/mL.
In conclusion, the developed model describes the time course of PANSS
scores adequately, and a recommendation of haloperidol dose was derived
for future antipsychotic drug trials.
Key Words: haloperidol, population
pharmacokinetics-pharmacodynamics, PANSS total, schizophrenia,
dropout model
(J Clin Psychopharmacol 2013;33: 731Y739)
Haloperidol, a typical antipsychotic, was the most widely useddrug for many years in the treatment of patients with schizo-
phrenia and other psychotic disorders.1 Haloperidol is still widely
used as the prototypical comparator antipsychotic for randomized
controlled trials. The effective dose of haloperidol is still not
known, which is a problem when it is used as a comparator drug.2
McEvoy et al3 recommended about 3 mg/d, whereas Van Putten
et al4 found that the efficacy increased with doses up to 20 mg/d.
The American Psychiatric Association guideline recommends a
broad range of 5 to 20 mg/d5 for the acute and the maintenance
treatment of schizophrenia symptoms. In addition, in many clin-
ical trials, higher doses of haloperidol are used as a comparator.
This may be linked to higher incidence of adverse effects such as
extrapyramidal side effects, and therefore comparison between
drugs could be biased.6 Recently, Giegling et al7 discussed a sta-
tistical strategy for choosing an appropriate dose and the corre-
sponding exposure of haloperidol for clinical studies based on the
observed response. However, the observed interindividual vari-
ability (IIV) in the pharmacokinetics (PK) and pharmacodynam-
ics (PD) of haloperidol was not fully characterized because of the
small sample size of patients. To our knowledge, there is no literature
available on population-based pharmacokinetic-pharmacodynamic
(PKPD) modeling of haloperidol using the Positive and Nega-
tive Syndrome Scale (PANSS) total score that would help in de-
termining the effective haloperidol dose. Hence, in the present
study, we developed a PKPDmodel that describes the time course
of the PANSS total scores accounting for the contributors to the
variability in the haloperidol exposure-response. Subsequently, a
methodology for estimating an effective dosing strategy (dose and
corresponding effective exposure) when haloperidol is used as a
comparator drug in clinical trials is described. To achieve these
goals, we applied a nonlinear mixed-effects modeling (NONMEM)
approach to describe the population PK (POP-PK) of haloperidol.
Consequently, the developed POP-PKwas used as an input model
for building the PKPD model that describes the time course of
PANSS total score accounting for the placebo effect, the variability
in exposure-response, and the dropouts. Based on the developed
PKPD model, we calculated the effective dose of haloperidol.
Furthermore, the developed PKPDmodel was utilized to quantify
the efficacy of haloperidol toward the PANSS subscales.
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MATERIALS AND METHODS
Participants and Study Design
In total, data from 515 patients were used to develop and to
evaluate the PK and PKPD model. The overview of the data sets
with their study design, patient demographics, summary statistics
of the PANSS scores, and dropout rates across the studies used
in the development of the PKPD model is shown in Table 1. In
brief, the population PK model for haloperidol was developed
from 7 studies, with data from 122 individuals (healthy volunteers
[n = 20] and schizophrenic patients [n = 102]) and 538 plasma
concentrations obtained from a wide dose range of 1 to 60 mg/d
administered either as a single or multiple doses. The studies that
provided PK data were well-controlled studies and were con-
ducted either to measure the dopamine-2 receptor occupancy
(D2RO) of haloperidol or to evaluate the effects of haloperidol on
the central nervous system. Studies with healthy volunteers pro-
vided a rich PK sampling. On the other hand, PANSS data from
4 studies in 473 schizophrenic patients with 2342 PANSS obser-
vations were utilized to describe the exposure-response relation-
ship of haloperidol. The data for PKPDmodelwere obtained from
3 phase III trials (via TI Pharmamechanism-based PK-PDmodeling
platform, the Netherlands; www.tipharma.com) and 1 open-label
study data from Ludwig Maximilians University (LMU) study.
All these studies were short-term (4-8 weeks) efficacy trials, with
the main inclusion criteria being a diagnosis of schizophrenia
under the Diagnostic and Statistical Manual of Mental Disorders
version III and an observed PANSS score of at least 60. In the
open-label study, patients were treated with haloperidol without
any dose limitation during the acute phase of the illness. All
studies were approved by their respective ethics review board and
were performed according to ethical standards laid down in the
1964 Declaration of Helsinki.
Model Development
A nonlinear mixed-effects modeling approach to describe
the time course of PK and PANSS scores was implemented using
the NONMEM VII software8 (ICON Development Solutions,
Hanover, MD). Perl-speaks-NONMEM9 (PsN, version 3.2.4) was
used to operate NONMEM. R (version 2.11; www.r-project.org)
was used for graphical inspection of the results. Log-transformed
plasma haloperidol concentrations were used to estimate the PK
parameters, whereas absolute PANSS scores were used for the
PD model. The first-order conditional estimation method with or
without interaction option in NONMEMwas used to estimate PK
and PKPD model parameters. First-order conditional estimation
along with the Laplace approximation method in NONMEMwas
utilized for estimating the dropout model parameters.10
Interindividual variability for the structural model parame-
ters was evaluated using a log-normally or a normally distributed
model:
Pj¼PTVexpðG jÞor Pj¼PTVþG j
where PTV represents the population typical value of the parame-
ter, and Pj is the value of the parameter for subject j; Gj denotes
an individual-specific random effect that distinguishes the value
of the jth subject from the PTV. The values of Gj are assumed to
be normally distributed with mean zero and variance U2. Inter-
individual variability is expressed as percent coefficient of varia-
tion (%CV).
The intraindividual or residual variability (RUV) describes
the error terms, which remain unexplained, and refers to, for ex-
ample, dosing inaccuracies, analytical assay error, or error in re-
cording sampling times, and structural model misspecifications.
An additive residual error model, which is proportionalwhen
log-transformed plasma concentrations are back transformed, was
used to describe RUV in the plasma concentration, whereas an
additive term was used to account for the unexplained variability
in PANSS score as shown in the following equations:
lnðyijÞ ¼ lnðy
¹
ijÞ þ ?ij : for PK model
yij ¼ y
¹
ij þ ?ij : for PD model
where yij is the jth observation in the ith individual, ŷij is the
corresponding model prediction, and Dij is a normally distributed
random error with a mean of zero and a variance of R2. Different
sigma values were estimated for PK and PD models.
Model selection was based on comparison of the objective
function values ($OFV: 3.84, corresponding to a P value of 0.05)
and the goodness-of-fit plots. Goodness-of-fit was assessed graph-
ically by evaluation of the agreement between observed and pre-
dicted plasma concentrations or PANSS scores, the range of
conditional weighted residuals, and uniformity of the distribution
of conditional weighted residuals about zero across the range of
the predicted concentrations or PANSS scores. The percentage
relative SEs (%RSEs) of the parameter estimates and reduc-
tions in both IIV and RUV were also used to discriminate be-
tween competing models. The $OFV and Kaplan-MeierYbased
visual predictive check (VPC) plots were used to choose the best
dropout model.
Influences of patient- and study-specific covariates such as
age, sex, bodyweight, dosage regimen (once daily vs twice daily),
subject type (healthy vs patients), and disease status (acute vs
chronic) were evaluated as possible explanatory variables for the
variability in the PKor PKPDmodel parameters. Covariate analysis
was performed in NONMEM using PsN with a stepwise forward
additive approach followed by a stepwise backward elimination
approach with P values of 0.05 and 0.01, respectively.9 Uncor-
related covariates were included in the model using different
functional forms such as linear, piece-wise linear, power, and
exponential functions.
Population PK Analysis
One- and two-compartment models with first-order absorp-
tion and with or without absorption lag time were evaluated. Pre-
specified subroutines (ADVAN2 or 4) in the NONMEM software
were used to model the time course of haloperidol exposure. The
available covariates were tested for their influence on clearance
(CL/F) and central volume of distribution (Vc/F). If no significant
effect of any of the tested covariates (eg, age, sex, body weight,
population type etc) was found, a fixed allometric relationship with
individual body weight and CL/F was assumed: CL/F = TVCL *
[weight / 70]0.75. This was done because the relationship between
body weight and clearance is well documented11 and allows for
taking into account IIV even in the studies where no individual
PK was known. Using post hoc empirical Bayesian step in
NONMEM, the individual parameter estimates were obtained.
PKPD Model
As a first step in building the exposure-response relationship,
a placebo model that was developed and validated previously12,13
was incorporated into the drug effect model such that the phar-
macological effectiveness of the drug was estimated on top of the
placebo effect. The time course of the placebo response could be
described using the Weibull model as described by Friberg et al.12
Previously reported predictors of variable placebo effect were also
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included in the placebo model.13 The treatment effect was
modeled as a relative change from the baseline PANSS score as
shown in the following equation:
PANSS Score ¼ Baseline PANSS 1 Pmax  1 e
j
time
TD
  POW0
BB@
1
CCA
0
BB@
1
CCA
2
664
 1 Emax  C ss
EC50 þ C ss
 
 ð1 e j KT timeÞÞ0BBB@
wherePmax is themaximum placebo effect, TD is the time to reach
63.2% of maximum change in PANSS from baseline; POW is the
shape parameter; Emax is the maximum drug effect; Css is the
patient-specific average steady-state plasma concentration, which
was estimated using the dose, dosing interval and the individual
estimate of CL/F values obtained from the final POP-PK model:
[Css = dose / CL/F / dosing interval]. For patients in whom PK
was not assessed or available, the population-based PK parameter
estimates from POP-PK model (adjusted for body weight) were
used for the predictions of PK profile. We assumed thatCss is con-
stant over the dosing interval, as little fluctuation in the exposure
can be anticipated once a patient reaches steady-state levels (ie,
after 5Y6 half-lives), and most PANSS observations were done
at steady-state conditions. EC50 is the steady-state concentration
required to achieve 50% of Emax, and KT is a rate constant associ-
ated with the time required to obtain the maximum drug effect.
Interindividual variability for baseline PANSS and EC50 was
assumed to be log-normally distributed. Normally distributed
IIV was used for Pmax and Emax parameters, which allows the pla-
cebo and drug effect to be positive (improvement, ie, decrease of
PANSS score) or negative (worsening, ie, increase in PANSS
score). All the parameters that were described in the above equa-
tion were estimated except 2 placebo model parameters, namely,
POWand TD, which were fixed, based on our earlier results. Dur-
ing the model development and simulations, the PANSS score
data were not constrained to fall within the rating scale range of
30 to 210 because attempts to constrain the model to predict/
simulate only scores between 30 and 210 resulted in numerical
difficulties during the estimation of the model parameters. More-
over, there were no simulated data points greater than 210, and
only 0.2% of the simulated data points were less than 30. The co-
variates of the placebo effect were fixed during the subsequent
PKPD modeling. The influences of clinically relevant covariates
such as disease condition, age, sex, and dosage regimen were test-
ed on drug effect parameters (Emax and EC50). We extended the
use of the developed PKPD model to the PANSS subscales (ie,
positive and negative subscales) accounting for their respective
placebo effects.
To predict the mean changes in the PANSS adequately via
simulations, it was necessary to account for the dropouts.13 The
exponential time-to-event dropout model was used jointly with
the PD model. The probability of a patient dropping out from a
trial can be predicted by describing the hazard for the dropout
event. Hazard is the instantaneous rate of the dropout event: h(t).
hðtÞ ¼ BHAZ expðj predictor BETAÞ
The model assumes that baseline hazard (BHAZ) is inde-
pendent of time and estimates the BHAZ and BETA as dropout
model parameters; BHAZ is baseline hazard without influence
of predictors, whereas BETA is a parameter that describes the
probability of a patient dropping out based on the predictors such
as observed PANSS score, unobserved (predicted), unobserved
(predicted) + observed PANSS, change in the PANSS score from
baseline, or drug exposure. Several predictors can be included
within the time-to-event model structure with parameterizing
different BETAs for each of the predictors. Cumulative hazard
(CHZ) predicts the risk of a patient dropping out from the study
over the time interval, which is obtained by integrating the hazard
over time. The probability of survival (not dropping out) can be
predicted from the cumulative hazard: S(t) = exp(jCHZ). Finally,
the probability of dropping out at time t is given by D(t) = S(t) 
h(t). The best predictor(s) of dropout was selected based on
the $OFV. A sequential approach14,15 was used to estimate the
dropout model parameters conditioning on the estimates of the
PKPD model.
Model Evaluation
The developed PK and PKPD models were evaluated by
bootstrap analysis and simulation-based methods within the
NONMEM software using PsN.9 One thousand bootstrap data
sets were obtained by resampling with replacement from the
original haloperidol data set with stratification based on study, and
then the final model was fitted to each of the bootstrapped data
sets. The bootstrap median and 2.5th and 97.5th percentiles were
obtained for each parameter from the distribution of parameter es-
timates from successful NONMEM estimation runs. These were
compared with the estimates obtained from the original data
set.16,17 The other model evaluationmethod used was the stochastic
simulation and estimation (SSE), which is a simulation-based tool
for evaluating model appropriateness and adequacy. The final
model was used to generate a number of simulated data sets, which
were subsequently fit to this input model. The median parameter
estimates of the simulations were compared with the final param-
eter estimates from the input model. The accuracy of parameter
estimates was measured by computing the % bias [bias = 100%
mean (estimated parameter j true parameter) / true parameter].
Monte Carlo simulations were performed for the final PK and
PKPD model to construct the VPC plots. In brief, 1000 data sets
identical in structure to the original PK and PKPD data set were
simulated, using the parameter estimates and interindividual and
intraindividual variability from the respective final models. Sep-
arate VPC plots were plotted for both the PK and PKPD models
after calculating the 2.5th, 50th, and 97.5th percentiles of plasma
concentrations or PANSS scores for the simulated data sets.
With respect to VPCs of the PK model, a VPC plot was con-
structed only for the LMU study where the steady-state plasma
haloperidol concentrations were available.
For the PKPD model, initially, simulations were performed
for the base PKPD model (without dropout model and predictors
of placebo effect). Subsequently, simulations for the final PKPD
model were performed along with the dropout model + predictors
of placebo effect and dropout model, in which the observed
PANSS scores were replaced with the simulated PANSS scores
from the final PKPD model. Then, VPC plots were plotted sep-
arately for different studies after calculating the 2.5th, 50th, and
97.5th percentiles of PANSS scores for the simulated data sets.
Calculations of the Haloperidol Therapeutic Dose
and Concentrations
Calculations of the haloperidol therapeutic dose and plasma
concentrations based on the final PKPDmodel using PANSS total
scores are discussed below. The PANSS scores corresponding to
the targeted % change were calculated based on the following
Pilla Reddy et al Journal of Clinical Psychopharmacology & Volume 33, Number 6, December 2013
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equation correcting for minimum possible PANSS total score
of 30.
% chage in PANSS Total ¼ PANSSj Baseline PANSS
Baseline PANSSj30
 100:
Rearranging the above equation,
PANSS ¼ change in PANSS total =100
ð Baseline PANSSj30Þ þ Baseline PANSS
The corresponding PANSS value is obtained using the esti-
mate of baseline PANSS from the final PKPD model and know-
ing the desired % change in PANSS score from baseline.
For example, with a targeted 30% reduction from baseline
with a baseline PANSS score of 90:
PANSS ¼ ðj 30=100Þ ð 90 j30Þ þ 90
will yield a PANSS score of 72. Above calculated PANSS was
then integrated into the equation describing the change in score
from baseline in our PKPD model: PANSS = baseline PANSS 
(1 j placebo effect)  (1 j drug effect). Assuming maximum
(at the end of the trial) placebo and drug effect, the equation
becomes
PANSS¼ Baseline PANSS ð1jP maxÞ


1jE max  C eff=ðC eff þ EC50Þ

:
After rearrangement of the above equation we obtain the
steady-state effective concentration (Ceff) necessary to reach the
targeted PANSS score:
C eff ¼ EC50=

E max=

1j PANSS=

Baseline PANSS ð1jP maxÞ

j1

:
The corresponding therapeutic dose is calculated using the
following relationship Effective dose (mg/d) = Ceff* CL/F. The
above calculations were also extended to PANSS subscales.
RESULTS
Haloperidol PK Analysis
Haloperidol PK following oral administration was best de-
scribed by a 2-compartmental model with first-order absorption.
The appropriateness of the 2-compartment over the 1-compartment
PK model was based on the visual comparison of goodness-of-fit
plots (Fig. 1; top panel) and the lower objective function value.
The ADVAN4 TRANS4 subroutines and the first-order condi-
tional estimation method with interaction option in NONMEM
were used to estimate the 2-compartment PK model parameters.
The final population PK parameters for haloperidol are shown in
Table 2. Interindividual variability could only be estimable for
CL/F and Vc/F. The unexplained variability (RUV) in the PK
model was 44%. This high variability may be partly caused by
lack of individual PK information for a number of patients. None
of the patient-related covariates in our data set influenced the
population typical PK parameters at the P level of 0.05. The
median parameter estimates obtained from the 985 successful
bootstrap replicates of the PK data were within 5% of those
obtained with the final PK model and the original data set. Me-
dian values of the parameter estimates from the SSE analysis are
in most cases in good agreement with the model-estimated
FIGURE 1. Goodness-of-fit-plots of the haloperidol final PK (top panel) and PKPDmodel (bottompanel). Gray line represents identity line,
and black line represents a LOESS fit. Dots are observed data.
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original value. The bias in the parameters estimates were not more
than 12% for all the PK parameters. A representative VPC plot
following 1000 simulations based on the final PKmodel is shown
in Figure 2.
Haloperidol PKPD Analysis
An Emax model was used to quantify the drug effect. To
quantify the exposure-response relationship of haloperidol, a
patient-specific steady-state plasma concentration was used. The
maximum placebo effect (Pmax) for a typical schizophrenic pa-
tient was estimated to be 0.081 (ie, the maximum relative decrease
in PANSS from the baseline PANSS score was 8.1%). The estimate
of Pmax and the placebo model fits were similar to our previously
reported work.13 The maximum drug effect (Emax) of haloperidol
was found to be 0.31 (ie, the maximum relative decrease in
PANSS score from baseline following haloperidol treatment on
top of the placebo effect was 31%). We explored different model
structures such as additive drug effect and combination of additive
placebo effect and proportional drug effect to the baseline PANSS
score to describe the time course of PANSS. Proportional relative
placebo/drug effect to baseline PANSS was found to be a better
and more stable model when compared with the other models.
The typical EC50 value for PANSS totalwas found to be 3.58 ng/mL.
The IIVof EC50 parameter (152% CV) was found to be relatively
large in our analysis. This high variability may be partly caused by
lack of individual PK information for a number of patients. To
investigate the effect of IIV-EC50 on the precision of the PD pa-
rameter estimates, we compared the models with estimating IIV-
EC50 and fixing IIV-EC50 at 50% CV. The PD parameter estimates
(Emax and EC50) were found to be comparable with similar pre-
cision. Hence, based on$OFVvalue, we choose the PKPDmodel
with estimating the IIV-EC50 for further model evaluation steps.
The bootstrap results from the 957 successful runs are shown
in Table 2. The difference between the median parameter estimates
obtained from the successful bootstrap replicates of the PKPD data
and those obtained with the final PKPD model with the original
data set were less than 2.5%. Moreover, the final parameter esti-
mates from the developed model were well within the bootstrap
95% confidence interval. Simulation-based (SSE) results indi-
cated that PKPD model parameters were estimated precisely
(Table 2). Case-by-case deletion diagnostics of the PKPD model
showed that the model parameters were robust and precise toward
the deletion of any one study (data not shown).
We extended the use of the developed PKPD model to the
PANSS subscales. The modelwas able to describe the time course
of positive and negative symptoms adequately without any further
TABLE 2. Summary of Haloperidol Final PK Model and Model Evaluation Results
Parameters
Original
Data Set (%RSE)
Bootstrap Results SSE Results
Median (95%
Confidence Interval) Median % Bias
PK model
CL/F (L/h) 88 (6) 89 (77Y101) 86 j2
Q/F (L/h) 233 (28) 225 (56Y391) 250 12
Vc/F (L) 669 (29) 637 (91Y1143) 700 9
Vp/F (L) 2500 (39) 2487 (573Y3565) 2715 12
Ka (hj1) 0.236 (18) 0.227 (0.056Y0.387) 0.235 6
IIV-CL (%CV) 44.5 (13) 44 (31Y55) 44 j0.5
IIV-Vc (%CV) 116 (14) 119 (95Y180) 122 j5
RUV proportional 0.44 (3) 0.44 (0.38Y0.50) 0.44 j6
PKPD model
Baseline PANSS 91.6 (1) 91.6 (90.8Y92.3) 91.7 0.5
Pmax 0.081 (9) 0.075 (0.064Y0.096) 0.083 4
Emax 0.31 (20) 0.34 (0.19Y0.66) 0.29 j2
EC50 (ng/mL) 3.58 (39) 4.03(1.89Y10.78) 2.71 j15
KT (1/d) 0.116 (4) 0.113 (0.062Y0.167) 0.12 6
t2 (delay in drug effect in days)* 6 V V V
BHAZ: placebo (1/d) 0.00139 (9) 0.00144 (0.0009Y0.0015) 0.00139 0.1
BHAZ: haloperidol (1/d) 0.0009 (9) 0.00087 (0.00066Y0.00111) 0.0009 0.1
BETA j0.0295 (2) j0.0292 (j0.0317 to 0.0271) j0.0292 j0.2
IIV Pmax (SD) 0.20 (4) 0.20 (0.19Y0.22) 0.21 j0.2
IIV baseline PANSS (%CV) 16 (4) 16 (15Y17) 16 j1
IIV Emax (SD) 0.29 (35) 0.28 (0.17Y0.48) 0.27 j7
IIV EC50 (%CV) 152 (48) 151 (76Y287) 138 16
RUV as SD (additive) 8.7 (1) 8.7 (8.3Y9.1) 8.6 0.1
*Calculated using equation t2 = 0.693 / KT. The IIV shrinkage values were less than 20% except for EC50 (950%). The RUV shrinkage was 16.2%.
The accuracy (bias %) in parameter estimation by the SSE method is computed as = 100  mean (estimated parameter j true parameter) / true
parameter. %CV = ¾U2 * 100.
BETA indicates parameter relating hazard to PANSS score; BHAZ, baseline hazard; CL/F, apparent clearance; EC50, concentration to achieve 50%
of Emax; Emax, maximum drug effect; ka, absorption rate constant; KT, rate constant to account for delay in drug effect; Pmax, maximum placebo effect;
Q/F, inter-compartmental clearance; RUV, residual unexplained variability; Vc, central volume of distribution; Vp, peripheral volume of distribution.
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modification. The predictors of the placebo effect (unpublished
data) for both symptoms were also accounted for in the model.
The efficacy of haloperidol (Emax) for positive symptoms was
approximately twice that of negative symptoms (0.48 vs 0.21),
respectively, and the corresponding EC50 values were 1.28 and
6.39 ng/mL (Table 3). The parameter estimates of both subscales
were estimated precisely with %RSE of less than 35%. Haloper-
idol exposure to produce a 30% change in PANSS total score from
baseline PANSS was found to be 2.7 ng/mL, and the corre-
sponding dose was 5.6 mg/d.
A dropout model based on the observed PANSS score was
selected for further evaluation. The BHAZ parameter describing
the hazard of a patient dropping out at baseline levels of covar-
iates or predictors may be different for different treatments; hence,
we estimated separate BHAZ for the placebo and the haloperidol
treatment.
The estimates of BHAZ for placebo and haloperidol were
found to be 0.0014 and 0.0009, respectively. The BETA param-
eter, which describes the hazard of a patient dropping out from a
trial based on the observed PANSS irrespective of treatment, was
estimated to be j0.0295. The value j0.0295 indicates that prob-
ability of a patient dropping out from a trial increased exponentially
with increasing PANSS score. Monte Carlo simulations were
performed along with the combined PANSS + dropout model +
covariates, in which the observed PANSS scoreswere replacedwith
the simulated PANSS scores from the final PKPD model after ac-
counting for dropouts and its predictors (see Supplementary Figure,
Supplemental Digital Content 1, http://links.lww.com/JCP/A210;
bottom panel). When dropout was ignored, the simulations
showed wide prediction intervals at the end of the study, whereas
the actual observed percentile intervals were much narrower (see
Supplementary Figure, Supplemental Digital Content 1; top panel
http://links.lww.com/JCP/A210). When the dropout model was
included in the simulations, the simulated prediction intervals
were in close agreement with those of the observed percentile
intervals, indicating that patients, who had higher PANSS, or
worsening of disease condition, had dropped out before the end of
the trial. The LMU study was an open-label study with a flexible-
dosage regimen in which the haloperidol dose was adjusted based
on psychotic symptoms and tolerability; therefore, it may have
some consequences on drug effect parameters.12 Omitting an
LMU study did not result in any marked changes in parameter
estimates, but resulted in less precise parameter estimate of EC50.
DISCUSSION
In clinical practice and drug development, an understanding
of the exposure-response relationship is crucial for the efficient
determination of a suitable therapeutic range for the majority of
patients. Population PKmodeling has been used in analyzing data
from clinical trials, as well as data derived from routine clinical
practice.18 This approach has the advantage of incorporating all
patient-related covariates into the PKPD model, whereas the con-
ventional noncompartmental approach of PK analysis considers
these factors as a burden for data analysis and hence to be con-
trolled.17 The nonlinear mixed-effects modeling approach allows
analyzing the data of all individuals at once and considers
interindividual and intraindividual random effects. This ensures
that confounding correlations and disparity that may occur in
observational data are properly accounted for.19
Dose-response analyses ignore drug-target interaction (eg,
binding, activation, transduction mechanisms) and do not take
individual differences in exposure into account. Thus, they are a
poor descriptor for understanding the system pharmacology. On
the other hand, exposure-response analysis linking dose, plasma
concentration, and clinical effects can support dosage adjustments
in patients where PK differences are expected to arise from factors
such as race or demography, disease, genetic polymorphism,
smoking, and drug interactions. In this regard, PKPD modeling
FIGURE 2. A representative VPC plot for the final PK model
(shown only for LMU data). The gray shaded areas represent the
95% confidence intervals of the corresponding 2.5th, 50th,
and 97.5th percentiles of the simulated data; the black dashed
area represents the 2.5th and 97.5th percentiles of the observed
data, and the black solid line represents the median of the
observed data.
TABLE 3. Calculated Effective Haloperidol Dose and Concentrations for PANSS Total, PANSS Positive, and PANSS Negative
Subscales at 30% Reduction in Score From Baseline
PKPD Model Estimated Parameters Effective
Concentration
(Ceff), ng/mL
Corresponding
Dose: Effective Dose =
Css  CL/F, mg/dBaseline Score Pmax Emax EC50
PANSS total 91.6 0.081 0.31 3.6 2.7 5.6
PANSS positive subscale 23.4 0.099 0.41 1.2 0.54 1.2
PANSS negative subscale 24.1 0.047 0.21 6.4 31 65
Ceff = EC50 / (Emax / (1 j PANSS / (baseline PANSS  (1 j Pmax))) j 1); % change in score is given by (PANSS j baseline PANSS) / (baseline
PANSS j number of PANSS items)  100.
*Number of PANSS items: PANSS total: 30; PANSS positive: 7; PANSS negative: 7.
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could be an excellent tool not only to characterize the time course of
drug effects but also to separate drug-specific and system-specific
factors contributing to the PD of a drug. Furthermore, simulations
can be performed using a developed PKPD model parameters
to answer ‘‘what if’’ scenarios, for example, for different doses,
dosing frequency, sample size selection, and trial duration for
future clinical trials. In this article, we have focused on exposure-
response analysis rather than optimizing the clinical trials.
So far, no population-based PKPD model is available for
haloperidol. The aim of this study was to develop a PKPD model
that quantifies the efficacy of haloperidol, accounting for the
placebo effect and dropouts. Subsequently, the developed PKPD
model was utilized to characterize an improved dosing strategy
(what dose and related exposure) for using haloperidol as a
comparator drug in future antipsychotic drug trials or observa-
tional clinical studies.
The current data analysis utilized pooled data from 3 ran-
domized controlled trials and 1 open-label clinical study, which
consists of heterogeneous populations including whites, black,
Asian, and Hispanic people. The parameter estimates from the PK
model were comparable to those reported in Japanese patients by
Yukawa et al.20 None of the tested demographic covariates had
a significant effect on haloperidol disposition. However, we used
a fixed allometric relationship with individual body weight as
the adjustment of clearance to body size as it reduced OFV and
uncertainty in the parameter estimates to a certain extent. The
paucity of PK information in the data set could have masked the
influence of covariates on haloperidol disposition. Nevertheless,
Yukawa et al20 reported that haloperidol oral clearance in Japanese
patients was affected by 4 covariates, namely, body weight, age,
dose, and antiepileptic drug comedication. Therefore, the effect of
covariates in patients from another race/ethnicity (eg, whites)
cannot be ruled out completely. We did not have plasma mea-
surements from the chronic patients, andCss for these patients was
calculated based on the population PK model adjusted to the
patient’s body weight, dose, and dosage regimen. Hence, we did
not succeed in quantifying precisely the influence of covariates
on the drug effect parameters such as EC50. However, based on
a population approach, the EC50 value for chronic patients was
found to be 8.5 ng/mL (data not shown). Santos et al21 reported
that a different therapeutic window for a subchronic and chronic
patient exists for haloperidol. This finding was further supported
with our covariate results, suggesting that chronic patients need
higher plasma levels than do the acute patients, which could be
due to development of resistance (eg, D2 receptor levels) by
chronic patients to haloperidol exposure. Using PK-PDmodeling,
it is possible to adjust the dose for a specific set of patients.
Because of the lack of information about reduced haloperi-
dol, that is, the mainmetabolite of haloperidol, metabolite kinetics
was not included in our PK model. However, evidence suggests
that the antipsychotic effect in patients with acute schizophrenia is
mainly due to parent drug, and there is no additional contribution
of reduced haloperidol.22 Hence, absence of metabolite kinetics
in our PK model may be of less concern while estimating the PD
parameters.
Haloperidol has a high affinity (Ki) to dopamine D2 receptors
(0.7 nM) and a slow rate of dissociation (0.017 minj1),23 whereas
it has a low affinity to other receptors such as 5-HT2A, D1, and
D3.24 Because of these pharmacological properties, it is hypoth-
esized that haloperidol may exhibit a lower potency toward the
negative symptoms.23 We used the final PKPD model to charac-
terize the efficacy of haloperidol toward the PANSS positive and
negative symptoms. Haloperidol exhibited a lower Emax for neg-
ative symptoms over positive symptoms; this finding is in line
with the hypotheses that the negative symptoms do not only
depend on dopaminergic hyperactivity, and the involvement of
other receptors plays an important role in exhibiting a better ef-
ficacy toward the negative symptoms.
At present, the PANSS total score is more commonly used
than the Brief Psychiatric Rating Scale. Thus, an investigation
was performed using the PANSS score as a clinical end point to
estimate the precise therapeutic dose or exposure range of halo-
peridol required in the clinic. Haloperidol exposure to produce a
30% change in PANSS total score from baseline PANSS was
found to be 2.7 ng/mL (Table 3), which is in agreement with the
effective mean concentration of haloperidol of 3.82 ng/mL as
reported by Giegling et al.7 The corresponding dose for a 30%
change in PANSS score from baseline PANSS was found to be
5.6 mg/d. The baseline PANSS was opted as reference in this
analysis, as in routine clinical practice, the % change in PANSS
score from baseline is the most commonly used end point. More-
over, in our case, not all studies were placebo-controlled trials,
not allowing the calculation of real drug effect from placebo.
To characterize the relationship between the clinical efficacy
and D2RO levels, we used the following relationship: D2RO =
ROmax * Ceff / (Kd + Ceff), where ROmax is the maximum receptor
occupancy, and Kd is the plasma level of haloperidol associated
with 50% of D2RO. The values of Kd (0.32 ng/mL) and ROmax
(84%) were directly obtained from a recent article by Uchida
et al,25 whereas the Ceff is calculated value (2.7 ng/mL) from our
final PKPDmodel and was used in the above equation to calculate
mean D2RO. The PKPD modelYderived haloperidol Ceff value
relates to 75% D2RO, which is in close agreement with the pre-
sumed D2RO therapeutic window of 65% to 80%.26,27
In the standard statistical analysis, the estimation of drug
effect may be influenced by the high placebo effect and the high
dropout rate. We used a model-based normalized placebo effect
after accounting for the predictors of placebo response to
quantify the drug effect. In addition, we demonstrated that joint
modeling of drug effect and dropout should be considered,13
while predicting the drug effect in clinical trials (see Supple-
mentary Figure, Supplemental Digital Content 1; bottom panel
http://links.lww.com/JCP/A210). The limitation of this work is
that we mainly focused on linking the exposure to the efficacy
parameters; however, an additional support for this choice of dose
by linking the exposure to safety parameters (eg, modeling of
extrapyramidal side effects) to further optimize the therapeutic
dose range of haloperidol is in progress. In conclusion, based on
our data analysis, the haloperidol recommended dose if used as a
comparator in clinical trials with diverse schizophrenic patients to
achieve a good clinical effect is 5.6 mg/d, and the corresponding
plasma haloperidol exposure is found to be 2.7 ng/mL.
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